Browse News

Found 491 articles

• CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS

  5/15/2023

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in infants.

• Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre

  7/26/2022

  Nuance Pharma announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV infusion, a non-opioid analgesic drug co-developed with Neumentum.

• Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

  5/24/2022

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) and Senores Pharmaceuticals, Inc. today announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).

• Medical Holography Market to Witness Comprehensive Growth by 2026

  5/19/2022

  Albany NY, United States: The global medical holography market features an extremely competitive market landscape with numerous market players focusing on the development of new products, reports Transparency Market Research.

• Omeros Corporation Reports First Quarter 2022 Financial Results

  5/10/2022

  Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2022.

• Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results

  3/1/2022

  Omeros Corporation (Nasdaq: OMER), today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021.

• Non-steroidal Anti-inflammatory Drugs Market: The Injectable Segment is Expected to Witness Rapid Growth Owing to Higher Efficacy

  2/18/2022

  Non-steroidal anti-inflammatory drugs is a class of powerful analgesics, distinguished by their non-steroidal chemical structure.

• Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical

  12/23/2021

  Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc . , an affiliate of Rayner Surgical Group Limited.

• Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion

  12/2/2021

  Omeros Announces Agreement to Sell OMIDRIA ® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion.

• Omeros Corporation Reports Third Quarter 2021 Financial Results

  11/9/2021

  Omeros Corporation announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2021, which include:

• Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial

  11/5/2021

  Omeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy.

• Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis

  11/5/2021

  Omeros Corporation (Nasdaq: OMER) today announced that the first report on urinary complement levels in kidney disease was presented yesterday at the Annual Meeting of the American Society of Nephrology.

• Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021

  11/4/2021

  Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, November 9, 2021, after the market closes.

• Postoperative Pain Market Size Estimated to Observe Significant Growth by 2024

  10/22/2021

  One of the main postoperative adverse outcomes is pain that causes prolonged hospital stay, physical distress and increasing incidences of readmissions of patients post surgery.

• Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA

  10/18/2021

  Omeros Corporation announced that the company received a Complete Response Letter from the U.S. Food and Drug Administration regarding its Biologics License Application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

• Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA

  10/1/2021

  Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA’s ongoing review of the company’s Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)

• Chronic Focal Encephalitis Market: An increase in the number of instances of chronic focal encephalitis

  9/21/2021

  Chronic focal encephalitis (CFE) is an uncommon but deadly inflammatory brain illness in which individuals fight their own immune system.

• Omeros Corporation Reports Second Quarter 2021 Financial Results

  8/9/2021

  Omeros Corporation (Nasdaq: OMER), today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2021.

• Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021

  8/3/2021

  Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

• Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association

  6/14/2021

  Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA).